December 20, 2024

Schizophrenia: NMI observes processes in nerve cells

Schizophrenia: NMI observes processes in nerve cells

Is it enough to treat the symptoms, or would we rather get to the causes of the illness? Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

Proteins play a central role in organisms in many respects. If they are incorrectly coded and/or do not carry out their tasks as planned, this can lead to diseases. This also applies to schizophrenia, in which nerve cells (neurons) develop incorrectly.

Early detection of faulty processes

A team of scientists at the NMI led by Aaron Stahl, Prof. Hansjürgen Volkmer and Dr. Markus Templin has now used DigiWest® technology to examine nerve cells during their development. They used patient-derived cells (provided by the University Hospital of Tübingen) from diseased and non-diseased individuals and subjected them to high-precision analysis.

“We have succeeded in observing neurons at an early stage of development. This enabled us to describe at an early stage that diseased cells develop worse and, above all, why,” explains Aaron Stahl, who conducts research at the NMI and the Faculty of Medicine at the University of Tübingen.

What happens in the nerve cells in schizophrenia?

The DigiWest® protein analyses provided an insight into important processes within diseased cells. It is now clear which processes are faulty. These include the repair of defective DNA. Cell cycle regulation, which determines the process of regular cell division, also no longer functions correctly. Finally, the so-called p53 regulation is significantly altered in these cells; it is already known that the protein p53 can trigger serious diseases such as cancer if it is incorrectly regulated. There appears to be a close connection between these malfunctions in the nerve cells and schizophrenia.

A step towards the goal of treating the causes of schizophrenia

“Thanks to our protein analyses, we now know much more about the actual triggers for schizophrenia. This is an important step on the way to possibly one day treating the disease closer to its causes with medication,” says NMI scientist Dr. Markus Templin, looking ahead. However, it will still take some time for science to achieve this goal.

Paper: Patient iPSC-derived neural progenitor cells display aberrant cell cycle control, p53, and DNA damage response protein expression in schizophrenia

Online https://doi.org/10.1186/s12888-024-06127-x

More information on the DigiWest® technology: https://www.nmi.de/biomarker-und-bioanalytik/dienstleistungen/digiwestr-protein-profiling-1

Our latest News

discover more
Universität Heidelberg with 16 “Highly Cited Researchers”

Universität Heidelberg with 16 “Highly Cited Researchers”

International evaluation names researchers whose publications have been most cited worldwide 16 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines. The […]

Universität Heidelberg: New DFG Research Unit in Oncology

Universität Heidelberg: New DFG Research Unit in Oncology

GenoMiCC consortium deals with functional genomics and microbiomics in colorectal cancer and is coordinated at the Medical Faculty Mannheim In the latest approval round of the German Research Foundation (DFG), Heidelberg University has been successful with a grant application for a new Research Unit in oncology. The GenoMiCC consortium pursues the goal of identifying new […]

Merck and Promega collaborate on 3D cell technology for drug discovery

Merck and Promega collaborate on 3D cell technology for drug discovery

Full text in German below. Merck und Promega arbeiten gemeinsam an 3D-Zelltechnologie für die Wirkstoffforschung Strategische Partnerschaft bündelt Know-how von Merck im Bereich Organoide mit Promegas Assay-TechnologienForschende erhalten besseren und schnelleren Zugang zu krankheitsrelevanten ZellmodellenStärkt Mercks Position bei zukunftsweisenden Tools und Lösungen auf dem Gebiet der Biologie Darmstadt, Deutschland. (06. November 2025) Merck, ein führendes Wissenschafts- […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp